Skip to main content
. 2021 May 6;12:686874. doi: 10.3389/fphar.2021.686874

FIGURE 2.

FIGURE 2

(A) Immunoblotting evaluated expression of cyclin D1, YAP, p-YAP, p53, p21, and pro-apoptotic marker PARP in KIT-independent GIST cell lines (GIST48B and GIST54) after treatment with bortezomib for 72 h. Actin stain is a loading control. Linear capture quantitation of immunoblotting chemiluminescence signals, using an ImageQuant LAS4000. Intensity values are standardized to the DMSO control. (B) Quantitative RT-PCR evaluations of CCND1, YAP, and TAZ transcript expression in GIST48B and GIST226 after treatment with bortezomib for 24 h. Data were normalized to DMSO control and represent the mean values (±s.d.) from triplicate assays, and were averaged from two independent experiments. Statistically significant differences between DMSO control and bortezomib treatment are presented as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.